Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Artiva Biotherapeutics (ARTV) Shares Outstanding (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Shares Outstanding for 3 consecutive years, with $424000.0 as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 98.25% year-over-year to $424000.0; the TTM value through Dec 2025 reached $424000.0, down 98.25%, while the annual FY2025 figure was $424000.0, 98.25% down from the prior year.
  • Shares Outstanding hit $24.6 million in Q4 2025 for Artiva Biotherapeutics, up from $424000.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $24.6 million in Q4 2025 and bottomed at $424000.0 in Q3 2025.
  • Average Shares Outstanding over 3 years is $11.5 million, with a median of $814202.0 recorded in 2024.
  • On a YoY basis, Shares Outstanding climbed as much as 2908.69% in 2025 and fell as far as 98.25% in 2025.
  • Artiva Biotherapeutics' Shares Outstanding stood at $809758.0 in 2023, then surged by 2899.86% to $24.3 million in 2024, then crashed by 98.25% to $424000.0 in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $424000.0, $24.5 million, and $24.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.